Rebecca Nunn 2/1/22 Rebecca Nunn 2/1/22

Tucson startup looks to human trials for drug to treat lung inflammation

Aqualung Therapeutics, a Tucson-based drug startup headed by a University of Arizona pulmonologist, has won a major investment

Rebecca Nunn 2/1/22 Rebecca Nunn 2/1/22

Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models

Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models ByACCESSWIRE Published February 1,

Rebecca Nunn 1/26/22 Rebecca Nunn 1/26/22

Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer

Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer TUCSON, AZ / ACCESSWIRE / January

Rebecca Nunn 1/18/22 Rebecca Nunn 1/18/22

Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor

Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor Tuesday,

Rebecca Nunn 12/7/21 Rebecca Nunn 12/7/21

CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase in San Francisco

CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech

Rebecca Nunn 8/26/21 Rebecca Nunn 8/26/21

Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition on October 6-7th

Rebecca Nunn 7/22/21 Rebecca Nunn 7/22/21

Dr. Garcia Grand Rounds at Houston Methodist: A Systems Biology Journey to DAMPen Acute Lung Inflammation

Rebecca Nunn 2/11/21 Rebecca Nunn 2/11/21

eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic’s Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients

eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic’s Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients LINK TO PRESS

Rebecca Nunn 7/21/20 Rebecca Nunn 7/21/20

Aqualung Takes Genomic Approach to COVID-19’s Killer Lung Inflammation

Targets Protein Linked To Acute Respiratory Distress Syndrome Aqualung Takes Genomic Approach to COVID-19’s Killer Lung Inflammation Andrew McConaghieandrew.mcconaghie@informa.com Executive Summary Acute